Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
36 results about "Combination vaccines" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Combination vaccines available for many years include diphtheria and tetanus toxoids and whole-cell pertussis vaccine (DTwP); measles-mumps-rubella vaccine (MMR); and trivalent inactivated polio vaccine (IPV).
The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.
The present invention belongs to the field of biotechnology, and specifically relates to a seven-component antigenAfrican swine fever combination vaccine. The present invention first provides a seven-component antigenAfrican swine fevernanoparticle combination composed of African swine fevervirus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen forms a nanoparticle containing the antigen or its antigenic epitope with a nanoparticle carrier; the seven-component antigen African swine fever nanoparticle combination can stimulate the body to produce a strong immune response; secondly, the present invention prepares a vaccine comprising the above-mentioned seven-component antigen African swine fever nanoparticle combination, and the seven-component antigen African swine fever nanoparticle vaccine has a good immune protection rate against the parent African swine fever strong strain, has no biosafety risk, and breaks through the problem that the existing African swine fever subunit vaccines at home and abroad cannot provide effective immune protection for pigs.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.
The present invention provides a virus polypeptide-proteinsubunit combination vaccine based on DNAnanotechnology, and a preparation method and application thereof, belonging to the technical field of biological products. A virus polypeptide-proteinsubunit combination vaccine based on DNAnanotechnology uses a tetrahedral framework nucleic acid formed by DNA chain assembly as a carrier, a proteinantigen that causes virus-specific T cell activation is coupled to one edge of the tetrahedral framework nucleic acid, and a virus B cellepitopepeptide is coupled to the four vertices of the tetrahedral framework nucleic acid. Among all virus subunit-peptide vaccines with framework nucleic acids, coupling SARS-Cvo-2N protein to the tetrahedral framework can induce CD4 in a variety of animal models. + T cell activation can induce higher antibody titers and an increase in the ratio of memory B cells to T cells, and can also induce stronger CD8 + T cell activation provides a new idea for constructing efficient viral peptide vaccines based on protein carriers.
The present invention relates to the field of veterinary vaccinology, specifically combination vaccines for swine. In particular, the present invention relates to a combination vaccine for protection against infection with the pathogens porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo), comprising a non-replicating immunogen for PCV2 and a non-replicating immunogen for Mhyo. The vaccine is characterized in that it is an oil-in-water emulsion comprising squalane, vitamin E acetate, and silica. In another embodiment, the present invention relates to a combination vaccine for protection against infection with the pathogens PCV2 and Mhyo by intradermal administration.
A composition, an in ovo vaccine, and a composition for use as a vaccine against coccidiosis. The compositions and vaccine include Eimeria oocysts from a precocious attenuated strain of E. acervulina, and from at least one precocious attenuated strain selected from E. maxima, E. praecox and E. tenella. The composition and vaccine can be administered in ovo to embryonated eggs of a domesticated bird. A combination vaccine for use in the prevention and / or treatment of an Eimeria infection and Infectious Bursal Disease (Gumboro disease) and a kit for use as a vaccine including the composition.
The invention discloses vaccine for coronavirus and influenza virus and method for preparation thereof. More specifically, the invention discloses seasonal viral vaccine i. e. coronavirus and influenza virus vaccine for prophylaxis of novel coronavirus (SARS-CoV-2) infection (COVID-19) and Influenza virus in mammals and method for preparation of such vaccine. The invention discloses the stable combination vaccine compositions of killed-inactivated SARS-CoV-2, Influenza virus (A and B strains) as antigens. The present invention further discloses method of adaptation and growth seasonal influenza (A and B) strains in cell culture and methods of inactivation and purification of influenza virus bulk antigen. The present invention also discloses SARS-CoV-2 vaccine formulation with inactivated Influenza viruses and use of the same to elicit immune response against the SARS-CoV-2 and Influenza viruses in mammals and humans.
The invention belongs to the field of biology, and discloses a recombinant plasmid, the recombinant plasmid comprises an expression vector and a target gene connected to the expression vector, and the target gene comprises an IFN gammagene and a T alpha 1 gene; the nucleotide sequence of the IFN gammagene is as shown in SEQ ID No. 1; the nucleotide sequence of the T alpha 1 gene is as shown in SEQ ID No. 2. The recombinant plasmid can significantly improve the level of an HI antibody after immunization, and the effect of the recombinant plasmid is more significant than that of a mixed preparation of a recombinant plasmid connected with an IFN gamma gene and a recombinant plasmid connected with a Talpha1 gene, which indicates that the selected specific IFN gamma gene and Talpha1 gene can generate obvious synergy after being cloned to a carrier at the same time; meanwhile, the invention further discloses a preparation method, a protein composition, application, a vaccine and a combined vaccine of the recombinant plasmid.
The invention relates to a protein comprising a protein M and / or a protein P. The protein can form a multimeric structure and is used for preparing a vaccine alone or in combination, the vaccine can stimulate a body to generate neutralizing antibodies against HMPV and / or HPIV and has broad spectrum, meanwhile, the protein has physical stability, and under physical extreme conditions, the protein can be used for preparing a neutralizing antibody against HMPV and / or HPIV. And good immunogenicity can also be maintained. When used together with an RSV vaccine, the vaccine has no mutual inhibition effect, and the immunogenicity of the vaccine can be improved.